How Analysts Feel About SPOTLIGHT INNOVATION (OTCMKTS:STLT) After Increase in Sellers?

January 7, 2018 - By Michael Collier

The stock of SPOTLIGHT INNOVATION (OTCMKTS:STLT) registered an increase of 275% in short interest. STLT’s total short interest was 1,500 shares in January as published by FINRA. Its up 275% from 400 shares, reported previously.

The stock decreased 14.40% or $0.03 during the last trading session, reaching $0.16. About 23,465 shares traded. Spotlight Innovation Inc. (OTCMKTS:STLT) has 0.00% since January 7, 2017 and is . It has underperformed by 16.70% the S&P500.

Spotlight Innovation Inc., a pharmaceutical company, acquires and develops proprietary therapies to address unmet medical needs with an emphasis on rare, emerging, and neglected diseases. The company has market cap of $5.49 million. It identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations , and contract manufacturing organizations (CMOs), as well as pursues product commercialization opportunities, including out-licensing and strategic partnerships. It currently has negative earnings. The firm is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer.

More notable recent Spotlight Innovation Inc. (OTCMKTS:STLT) news were published by: which released: “Spotlight Innovation Subsidiary Caretta Therapeutics Engages Public Relations …” on July 11, 2017, also with their article: “Spotlight Innovation Inc. Issues Statement About Recent Stock Trading Activity” published on June 21, 2017, published: “Spotlight Innovation Appoints John Krohn President and Chief Operating Officer” on January 10, 2017. More interesting news about Spotlight Innovation Inc. (OTCMKTS:STLT) were released by: and their article: “Spotlight Innovation Launches Development of STL-182 to Treat Spinal Muscular …” published on October 19, 2016 as well as‘s news article titled: “Spotlight Innovation Makes Strategic Investment in Solx, Inc.” with publication date: November 30, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: